Maze Therapeutics (NASDAQ:MAZE) Upgraded to Strong-Buy at Citigroup

Maze Therapeutics (NASDAQ:MAZE) was upgraded by equities research analysts at Citigroup to a “strong-buy” rating in a report issued on Wednesday, Zacks reports.

Several other brokerages also recently commented on MAZE. Wedbush reaffirmed an “outperform” rating and set a $48.00 price objective on shares of Maze Therapeutics in a research note on Wednesday. Wall Street Zen cut Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. HC Wainwright restated a “buy” rating and set a $110.00 price target on shares of Maze Therapeutics in a report on Thursday. BTIG Research reaffirmed a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research report on Tuesday. Finally, TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Four analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Maze Therapeutics presently has an average rating of “Buy” and a consensus target price of $63.40.

Maze Therapeutics Stock Down 6.7%

Shares of NASDAQ MAZE opened at $26.21 on Wednesday. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09. Maze Therapeutics has a 52 week low of $21.95 and a 52 week high of $53.65. The firm’s fifty day moving average is $27.16 and its 200 day moving average is $29.04. The company has a market cap of $1.46 billion, a price-to-earnings ratio of -10.40 and a beta of 2.17.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, meeting the consensus estimate of ($0.76). On average, equities research analysts expect that Maze Therapeutics will post -2.72 earnings per share for the current year.

Insider Activity at Maze Therapeutics

In other Maze Therapeutics news, CMO Harold Bernstein sold 16,142 shares of Maze Therapeutics stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $27.61, for a total transaction of $445,680.62. Following the sale, the chief marketing officer directly owned 16,142 shares of the company’s stock, valued at approximately $445,680.62. The trade was a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $26.29, for a total value of $907,031.29. Following the transaction, the chief executive officer owned 18,151 shares in the company, valued at $477,189.79. This trade represents a 65.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 191,459 shares of company stock worth $5,263,539 over the last 90 days. 5.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Maze Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Frazier Life Sciences Management L.P. lifted its position in Maze Therapeutics by 10.2% during the second quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock valued at $150,182,000 after buying an additional 465,641 shares during the period. TRV GP IV LLC bought a new stake in Maze Therapeutics during the second quarter worth about $133,502,907. ARCH Venture Management LLC purchased a new stake in Maze Therapeutics in the second quarter worth about $122,983,582. BlackRock Inc. purchased a new stake in Maze Therapeutics in the second quarter worth about $104,525,000. Finally, Jupiter Topco LLC bought a new position in shares of Maze Therapeutics during the second quarter valued at approximately $101,764,000.

Trending Headlines about Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: New buy ratings support the investment case. Citigroup and BTIG both initiated coverage with Buy ratings and $50 price targets, implying substantial upside from the recent $26.21 reference price. Correction: Citigroup Initiates Maze Therapeutics at Buy With $50 Price Target BTIG Initiates Maze Therapeutics at Buy With $50 Price Target
• Positive Sentiment: Existing analysts remain bullish. HC Wainwright reaffirmed its Buy rating and $110 target, while Wedbush maintained an Outperform rating with a $48 target. These targets reflect analysts’ confidence in Maze’s pipeline, although they also indicate considerable execution risk for a clinical-stage biotechnology company. HC Wainwright Reaffirms Maze Therapeutics Buy Rating
• Positive Sentiment: Recent coverage has generated investor interest. Shares rose 2.9% after CIBC initiated coverage, indicating that new brokerage coverage can provide short-term support for MAZE. Maze Therapeutics Shares Rise 2.9% After CIBC Initiates Coverage
• Neutral Sentiment: Reported short interest is zero shares. The September 24 report lists no short positions and a 0.0-day short-interest ratio. This removes evidence of meaningful short-selling pressure or squeeze potential, though the figure may reflect a reporting or data anomaly rather than a fundamental change.
• Neutral Sentiment: Sector news is supportive but indirect. Strong results for a rival kidney-drug developer may reinforce interest in the biotechnology and renal-disease markets, but the development does not directly change Maze’s financial results or clinical outlook. Vertex’s Kidney Drug Success Sparks a 22% Surge for This Rival Biotech

Maze Therapeutics Company Profile

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.